{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T05:08:42Z","timestamp":1697432922217},"reference-count":46,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2002,1,4]],"date-time":"2002-01-04T00:00:00Z","timestamp":1010102400000},"content-version":"vor","delay-in-days":1313,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1998,6]]},"abstract":"<jats:p> <jats:bold>\n            <jats:italic>Aims<\/jats:italic>\n          <\/jats:bold>\u2007To examine the feasibility of using the human iris <jats:italic>in vivo<\/jats:italic> for the assessment of the interaction between tyramine and monoamine oxidase (MAO) inhibitors. To examine the relative roles of the two forms of MAO in terminating the response to sympathomimetic amines in the iris, by comparing the effects of single oral doses of moclobemide, a selective MAO\u2010A inhibitor, and selegiline, a selective MAO\u2010B inhibitor, on mydriatic responses to tyramine.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Methods<\/jats:italic>\n          <\/jats:bold>\u2007Twelve healthy male volunteers participated in three monthly sessions, each associated with ingestion of one capsule (moclobemide 450\u2003mg, selegiline 10\u2003mg, or placebo), according to a double\u2010blind, balanced, cross\u2010over design. Tyramine hydrochloride eye\u2010drops (75\u2003mm, 2\u00d710\u2003\u03bcl) were instilled three times in the left conjuctival sac at 40\u2003min intervals. Pupil diameter was monitored with a binocular infrared television pupillometer before and for 4.5\u2003h after ingestion of the capsule. The pupillary response to tyramine was expressed as the area under the pupil diameter\u00d7time curve (arbitrary units). A blood sample was taken before and 2\u2003h after ingestion of the capsule, for the assay of platelet MAO\u2010B activity, and plasma 3,4\u2010dihydroxyphenylglycol (DHPG) concentration, an index of MAO\u2010A activity. Platelet MAO activity was assayed radiochemically, using [<jats:sup>14<\/jats:sup>C]\u2010phenylethylamine as substrate, and plasma DHPG by high performance liquid chromatography (h.p.l.c.). The results were analysed using analysis of variance with repeated measures, followed by Bonferroni's corrected <jats:italic>t<\/jats:italic>\u2010test, using a significance criterion of <jats:italic>P<\/jats:italic>&lt;0.05.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Results<\/jats:italic>\n          <\/jats:bold>\u2007Both moclobemide and selegiline, compared with placebo, caused significant miosis in the right (untreated) eye. The changes in pupil diameter (mm\u00b1s.e. mean) from the pretreatment measurement were: placebo \u22120.09\u00b10.07, moclobemide \u22120.52\u00b10.09, selegiline \u22120.26\u00b10.1. The mydriatic response to tyramine was potentiated by moclobemide, compared with the response recorded in the presence of placebo. The responses to tyramine (arbitrary units\u00b1s.e. mean) were: placebo 77.08\u00b111.65, moclobemide 140.25\u00b118.9, selegiline 72.75\u00b112.35. Both moclobemide and selegiline significantly reduced platelet MAO activity, compared with placebo. The changes in platelet MAO activity (nmol\u2003h<jats:sup>\u22121<\/jats:sup>\u2003mg<jats:sup>\u22121<\/jats:sup> protein\u00b1s.e. mean) from the pretreatment level were: placebo 0.5\u00b10.62, moclobemide \u22126.7\u00b10.66, selegiline \u221217.7\u00b10.87. Moclobemide significantly reduced plasma DHPG concentration, compared with placebo. The changes in plasma DHPG concentration (nmol\u2003l<jats:sup>\u22121<\/jats:sup>\u00b1s.e. mean) from the pretreatment level were: placebo \u22120.01\u00b10.24, moclobemide \u22124.98\u00b10.32, selegiline \u22120.51\u00b10.26.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Conclusions<\/jats:italic>\n          <\/jats:bold>\u2007The potentiation of tyramine\u2010evoked mydriasis by moclobemide is likely to reflect the inhibition of MAO\u2010A activity in the iris, consistent with the activity of this enzyme in sympathetic nerve terminals. The lack of effect of selegiline on tyramine\u2010evoked mydriasis argues against a role of MAO\u2010B in terminating the effects of sympathomimetic amines in the iris. The effects of the two drugs on platelet MAO activity and plasma DHPG concentration are in agreement with previous reports and consistent with the relative selectivity of moclobemide for MAO\u2010A and of selegiline for MAO\u2010B. The miosis caused by the two MAO inhibitors is likely to be due to a central sympatholytic action of the drugs.<\/jats:p>","DOI":"10.1046\/j.1365-2125.1998.00729.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:30:50Z","timestamp":1047357050000},"page":"551-558","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of the effects of moclobemide and selegiline on tyramine\u2010evoked mydriasis in man"],"prefix":"10.1111","volume":"45","author":[{"given":"P.","family":"Bitsios","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. W.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Tavernor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Pyykk\u00f6","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Scheinin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Szabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. M.","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,4]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0301-0082(94)90081-7"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","unstructured":"MurphyDL SunderlandT GarrickNA AulakhCS CohenRMSelective amine oxidase inhibitors: basic to clinical studies. InClinical Pharmacology in Psychiatry eds Dahl SG Gram LF Paul SM Potter WZ Berlin: Springer\u2010Verlag 1987:135\u2013146","DOI":"10.1007\/978-3-642-71288-3_16"},{"key":"e_1_2_6_4_2","unstructured":"BroadleyKJAutonomic pharmacology.London: Taylor & Francis 1996"},{"key":"e_1_2_6_5_2","unstructured":"SzabadiE BradshawCMAffective disorders: 1. Antidepressants. InSeminars in Clinical Psychopharmacology ed King DJ London: Royal College of Psychiatrists\/Gaskall 1995:138\u2013192"},{"key":"e_1_2_6_6_2","first-page":"18","article-title":"Pharmacology of moclobemide.","volume":"16","author":"Haefely W","year":"1993","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01292628"},{"key":"e_1_2_6_8_2","unstructured":"KnollJThe pharmacology of (\u2010) deprenyl.J Neural Transmission1986;22S:75\u201389"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199300730-00001"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","unstructured":"ElizanTS(\u2010) Deprenyl combined with L\u2010DOPA in the treatment of Parkinson's disease. InInhibitors of monoamine oxidase B ed Szelenyi I Basel: Birkh\u00e4user Verlag 1993:277\u2013288","DOI":"10.1007\/978-3-0348-6348-3_14"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1968.tb00990.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00172970"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00431747"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.113.497.349"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02285092"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00426954"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1975.tb02787.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1980.tb04804.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb02691.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1996.03202.x"},{"key":"e_1_2_6_21_2","article-title":"Interactions of monoamine oxidase inhibition and sympathomimetic amines on the human iris.","volume":"41","author":"Bevan\u2010Jones B","year":"1971","journal-title":"Br J Pharmacol"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00619299"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1979.tb13428.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01127.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb05357.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb05710.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.204"},{"key":"e_1_2_6_28_2","article-title":"Comparison of the effects of moclobemide and selegiline on tyramine\u2010evoked mydriasis in man.","volume":"43","author":"Bitsios P","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(77)90043-4"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04341.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(91)90581-U"},{"key":"e_1_2_6_32_2","article-title":"Modification of the pupillary light reflex by miotic and mydriatic drugs: applicability of model of functional interaction.","volume":"23","author":"Longmore J","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1988.tb05307.x"},{"key":"e_1_2_6_34_2","first-page":"357","article-title":"Lichtevozierte dynamische Pupillometrie zur Differenzierung psychotroper Substanzen.","volume":"37","author":"Gr\u00fcnberger Von J","year":"1987","journal-title":"Drug Res"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04762.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00143886"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198606000-00001"},{"key":"e_1_2_6_38_2","first-page":"6","article-title":"Autonomic pharmacology of \u03b12\u2010adrenoceptors.","volume":"10","author":"Szabadi E","year":"1996","journal-title":"J Psychopharmacol"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(96)81564-1"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00166896"},{"key":"e_1_2_6_41_2","unstructured":"LoewenfeldIEPupillary pharmacology. InThe pupil ed Loewenfeld IE Iowa City: Iowa State University Press 1993 683\u2013827"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90127-1"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050489"},{"key":"e_1_2_6_44_2","first-page":"109","article-title":"Phenylisopropylmethylpropynylamine (E\u2010250), a monoamine oxidase inhibitor antagonising the effects of tyramine.","volume":"18","author":"Knoll J","year":"1968","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_45_2","first-page":"393","article-title":"Some puzzling effects of monoamine oxidase inhibitors.","volume":"5","author":"Knoll J","year":"1972","journal-title":"Adv Biochem Psychopharmacol"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1994.tb00378.x"},{"key":"e_1_2_6_47_2","first-page":"205","article-title":"An analysis of ephedrine mydriasis in relationship to iris pigmentation in the guinea\u2010pig eye in vitro.","volume":"171","author":"Seidehamel RJ","year":"1970","journal-title":"J Pharmacol Exp Ther"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1998.00729.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1998.00729.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1365-2125.1998.00729.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1998.00729.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T03:54:21Z","timestamp":1694404461000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.1998.00729.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,6]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1998,6]]}},"alternative-id":["10.1046\/j.1365-2125.1998.00729.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.1998.00729.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,6]]}}}